About TG Therapeutics
TG Therapeutics is a publicly listed company based in New York (United States) founded in 1993. Treatments for B-cell malignancies and autoimmune diseases are developed. It operates on a HealthTech model. TG Therapeutics has raised $25 million across 1 funding round. The company has 338 employees. TG Therapeutics has completed 1 acquisition, including Manhattan Pharmaceuticals. Its website tgtherapeutics.com draws about 29 thousand monthly visits. TG Therapeutics offers products and services including BRIUMVI (ublituximab-xiiy), Ublituximab, Azer-cel, and TG-1701. Its focus areas include Biotechnology and Pharmaceuticals. Its legal entity is TG Therapeutics, Inc. Its competitors include C4 Therapeutics, Erasca and MiRagen; 3 of its 3 listed competitors have raised funding.
Company details
TG Therapeutics, Inc. is engaged in the development and commercialization of innovative therapies for relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The companys primary product, BRIUMVI (ublituximab-xiiy), is approved by the U.S. FDA for adult patients. Additional pipeline candidates such as Ublituximab, Azer-cel, and TG-1701 are being explored for various therapeutic applications. The focus is placed on advancing scientific research and clinical trials to address unmet needs in the healthcare sector, particularly in neurology and immunology.
- Headquarters New York, United States
- Employees 338
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website tgtherapeutics.com
- Social LinkedIn X
- Legal Name Tg Therapeutics, Inc.
- Annual Revenue$616.29 M (USD)87.32as on Dec 31, 2025
- Net Profit$447.18 M (USD)1812.41as on Dec 31, 2025
- EBITDA$125.32 M (USD)196.89as on Dec 31, 2025
- Total Equity Funding$25M (USD)
in 1 rounds
- Latest Funding Round$25M (USD), Private Equity Round
Feb 2012
- Employee Count338
- Investments & Acquisitions
Products & Services of TG Therapeutics
TG Therapeutics offers a comprehensive portfolio of products and services, including BRIUMVI (ublituximab-xiiy), Ublituximab, Azer-cel, and TG-1701.
BRIUMVI is used for treating relapsing multiple sclerosis.
Ublituximab is developed for multiple sclerosis treatment.
Azer-cel is explored for potential therapeutic applications.
TG-1701 is investigated for various medical conditions.
Funding Insights of TG Therapeutics
TG Therapeutics has successfully raised a total of $25M through 1 strategic funding round. The most recent funding activity was a Private Equity Round of $25 million completed in February 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $25M
- Total Rounds 1
- Last Round Private Equity Round — $25M
- First Round $25M
(Feb 2012)
All 1 funding rounds of TG Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2012 | $25M | Private Equity Round | – | – | – |
People of TG Therapeutics
184 people are tracked at TG Therapeutics (146 in leadership, 5 in board & advisors, 33 in team); the tracked headcount is 338.
| Name | Role | Group |
|---|---|---|
Brian Fisk | Associate Director, Key Accounts | Leadership |
Kim Urban | Senior Director, Access And Reimbursement | Leadership |
Lisa Jordan | Associate Director, Access & Reimbursement | Leadership |
Allisan Smith | Associate Director, Access And Reimbursement | Leadership |
Bob Broach | Director, Market Access Account Management | Leadership |
Andrew Odenwald | Director, Market Access Account Management | Leadership |
Jamie Babich | Associate Director MS Regional Marketing | Leadership |
Rebecca O. | Associate Director - Key Accounts - Multiple Sclerosis | Leadership |
Nick Ward | Associate Director Of Key Accounts | Leadership |
Sheri Ellis Rn, Bsn | Associate Director, Clinical Research & Operations | Leadership |
Andrea Riddle | Associate Director- Regional Marketing | Leadership |
Jaclyn Frangioni | Associate Director, Access & Reimbursement | Leadership |
Karen Dinh | Associate Director, Quality Operations | Leadership |
Jesse McCrea | Executive Director, Commercial Finance Operations | Leadership |
Adam Waldman | Chief Commercialization Officer | Leadership |
Sean A. Power | Chief Financial Officer | Leadership |
Michael S. Weiss | Chairman, President, & CEO | Leadership |
Greg Gorman | Associate Director, Key Accounts | Leadership |
Stuart Ruwe | Associate Director, Regional Marketing | Leadership |
Rachelle Kienlen Access and Reimbursement Manager | Associate Director, Access And Reimbursement | Leadership |
164 more people are available in the full profile.
Complete people profiles for TG Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of TG Therapeutics
TG Therapeutics is a publicly listed company on the NASDAQ with ticker symbol TGTX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date14 Dec 1995
- Listed onNASDAQ: TGTX
- Listed entityTG Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS88322Q1085
- Share price$54.34 (-1.68% on the day) · 2026-10-13
- Market capitalisation$8.32B
- Price to earnings19.8
- EPS (diluted, trailing year)$2.75
- Volume (last session)1,001,269
Financials of TG Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $616.3M | $447.2M | $125.3M |
| 2024 | $329.0M | $23.4M | $42.2M |
| 2023 | $233.7M | $12.7M | $21.1M |
| 2022 | $2.8M | -$198.3M | -$192.3M |
| 2021 | $6.7M | -$348.1M | -$344.3M |
Detailed financial statements for TG Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by TG Therapeutics
TG Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Manhattan Pharmaceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
R&D company focused on manufacturing drugs for multiple therapeutic areas | manhattanpharma.com | New York, United States | 2003 | Apr 2012 | •••• |
Complete acquisition details for TG Therapeutics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of TG Therapeutics
4 dated milestones of TG Therapeutics across 19 years, from founding to its latest funding, stage changes and deals.
- Founded TG Therapeutics is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $25.0M.
- Acquisition Acquires Manhattan Pharmaceuticals.
Competitors of TG Therapeutics
TG Therapeutics has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and MiRagen.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. |
Detailed competitors of TG Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of TG Therapeutics
The website of TG Therapeutics (tgtherapeutics.com) receives about 29.4K visits a month and ranks #1,758,849 among all websites worldwide, #2,387 in Biotechnology and Pharmaceuticals.
- Monthly visits29.4K
▲ 95.5% vs previous month
- Unique visitors7.2K
per month
- Global rank#1,758,849
among all websites
- Category rank#2,387
Health · Biotechnology and Pharmaceuticals
- Bounce rate45%
- Pages per visit1.5
- Average visit12 sec
- DevicesDesktop 26% · Mobile 74%
Websites whose visitors overlap most with TG Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| mustangbio.com | 100% | 4.1K | #4,179,097 | View details | |
| syntheticbiologics.com | 92% | View details | |||
| esperion.com | 87% | 16.4K | #1,899,294 | View details | |
| onconova.com | 86% | View details | |||
| argostherapeutics.com | 84% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for TG Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as TG Therapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Tg Therapeutics
Complete news archive for TG Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about TG Therapeutics
TG Therapeutics was founded in 1993 and raised its 1st funding round 19 years after it was founded.
TG Therapeutics is headquartered in New York, United States. It is registered at New York, New York, United States.
TG Therapeutics is a funded company, having raised a total of $25M across 1 funding round to date. The company's 1st funding round was a Private Equity Round of $25M, raised on Feb 2012.
TG Therapeutics has 338 employees.
Annual revenue of TG Therapeutics is $616.29M as on Dec 31, 2025.
TG Therapeutics, Inc. is engaged in the development and commercialization of innovative therapies for relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The companys primary product, BRIUMVI (ublituximab-xiiy), is approved by the U.S. FDA for adult patients. Additional pipeline candidates such as Ublituximab, Azer-cel, and TG-1701 are being explored for various therapeutic applications. The focus is placed on advancing scientific research and clinical trials to address unmet needs in the healthcare sector, particularly in neurology and immunology.
TG Therapeutics's top competitors include C4 Therapeutics, Erasca and MiRagen.
TG Therapeutics offers BRIUMVI (ublituximab-xiiy), Ublituximab, Azer-cel, and TG-1701.
Yes, TG Therapeutics is publicly traded on NASDAQ under the ticker symbol TGTX.
TG Therapeutics has made 1 acquisition, including Manhattan Pharmaceuticals.
TG Therapeutics operates through Tg Therapeutics, Inc..